Phase III Clinical Trial of Telitacicept Injection in the Treatment of Patients With Connective Tissue Disease-related Interstitial Lung Disease

NCT07495033 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

260

Enrollment

INDUSTRY

Sponsor class

Conditions

CTD-ILD

Interventions

DRUG: Telitacicept
DRUG: Placebo

Sponsor

RemeGen Co., Ltd.